LBP-EC01
AXP000215.1 · Phage therapy
- Platform
- CRISPR-Cas3-enhanced phage cocktail (crPhage)
- Originator
- Locus Biosciences
- Sponsor
- Locus Biosciences
Names
| Name | Type | Source |
|---|---|---|
| LBP-EC01 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Escherichia coli bacteriophage (six-phage cocktail)
- Replication
- replicating
- Modifications
- each phage carries a CRISPR-Cas3 cassette targeting the E. coli genome
- Transgenes
- CRISPR-Cas3
- Route
- intraurethral, intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05488340 | A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) | Recruiting | Phase 2 | 2022-07-13 | 2027-06 | 318 | Urinary Tract Infections |
| NCT04191148 | Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli | Completed | Phase 1 | 2019-12-30 | 2020-11-19 | 36 | Urinary Tract Infections |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39134085 | Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. | The Lancet. Infectious diseases | 2024 | cited by trial NCT05488340 |
| PMID 33310655 | Enhancing phage therapy through synthetic biology and genome engineering. | Current opinion in biotechnology | 2021 | cited by trial NCT04191148 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42199538 | CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges. | Frontiers in microbiology | 2026 | name in abstract: LBP-EC01 |
| PMID 42262436 | CRISPR-based gene editing for antimicrobial resistance control in human medicine. | Archives of microbiology | 2026 | name in abstract: LBP-EC01 |
| PMID 43010175 | Engineered bacteriophages as precision antimicrobials against multidrug-resistant ESKAPE pathogens: molecular engineering strategies, clinical translation, and the crystallizing global regulatory landscape. | Future science OA | 2026 | name in abstract: LBP-EC01 |
| PMID 40733529 | Armed Phages: A New Weapon in the Battle Against Antimicrobial Resistance. | Viruses | 2025 | name in abstract: LBP-EC01 |
Notes
Cocktail of six Escherichia coli phages, each carrying a CRISPR-Cas3 cassette that cuts the E. coli genome. Phase 1b NCT04191148 dosed it by intraurethral instillation; the phase 2 ELIMINATE trial NCT05488340 gives intraurethral plus intravenous doses. Target bacterium is not an HGNC symbol, so targets is empty.
How to cite
LBP-EC01 (AXP000215.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000215.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.